This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ENDP Endo International (ENDP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Endo International Stock (NASDAQ:ENDP) 30 days 90 days 365 days Advanced Chart Get Endo International alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.28▼$0.7552-Week Range N/AVolume9,967 shsAverage Volume28.19 million shsMarket Capitalization$141 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Read More Endo International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreENDP MarketRank™: Endo International scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Endo International. Earnings and Valuation0.0 / 5Proj. Earnings Growth-83.33% Earnings GrowthEarnings for Endo International are expected to decrease by -83.33% in the coming year, from $0.78 to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ENDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEndo International does not currently pay a dividend.Dividend GrowthEndo International does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-2.62 Short InterestThere is no current short interest data available for ENDP. News and Social Media0.6 / 5News Sentiment0.01 News Coverage This WeekMarketBeat has tracked 9 news articles for Endo International this week, compared to 4 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Endo International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Endo International is held by insiders.Percentage Held by Institutions80.39% of the stock of Endo International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Endo International's insider trading history. Receive ENDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENDP Stock News HeadlinesGE Vernova Rides Electricity Boom as Cramer Endorses Stock and Price Target Climbs5 hours ago | finance.yahoo.comCintas Gains Cramer Endorsement as Long-Term Buy Ahead of Q1 Results5 hours ago | finance.yahoo.comTrump’s Senior Adviser Sparks a Wealth Shakeup"A Strange Day Is Coming to America... And You Could Lose 40% Of Your Wealth." One former Goldman Sachs exec just went public to warn of a huge event in 2025. He says this may be just the beginning of an orchestrated financial reset that could wipe out 40% of your wealth. He predicted the 2022 crash months in advance... and today, he's revealing the shocking White House plan that could rock your retirement - plus the three money moves you must make to prepare immediately.September 16 at 2:00 AM | Stansberry Research (Ad)Occidental Petroleum: Will Buffett's Endorsement Be Enough To Overshadow High Debt?September 16 at 8:51 AM | seekingalpha.comEDAP TMS SA's Focal One® HIFU Wins 2025 Industry Award for Innovations in Endourological InstrumentationSeptember 16 at 7:30 AM | quiverquant.comQDonald Trump Slaps New York Times With $15 Billion Lawsuit, Accuses Of Bias, Illegal Donations And 'Unheard Of' Harris EndorsementSeptember 16 at 3:11 AM | benzinga.comThe Wealth Tax Plan That’s Roiling New York and French PoliticsSeptember 15 at 10:11 AM | nytimes.comMEG Energy Endorses Cenovus Deal Over Strathcona OfferSeptember 15 at 8:11 AM | tipranks.comSee More Headlines ENDP Stock Analysis - Frequently Asked Questions How were Endo International's earnings last quarter? Endo International plc (NASDAQ:ENDP) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.34. The company's quarterly revenue was up 21.6% on a year-over-year basis. What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endo International investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Bank of America (BAC), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings11/04/2021Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENDP CIK1593034 Webwww.endo.com Phone(531) 268-2000Fax800-329-3636Employees3,103Year Founded1997Profitability EPS (Trailing Twelve Months)($11.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$613.24 million Net Margins-93.31% Pretax Margin-91.14% Return on Equity-34.25% Return on Assets6.72% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.62 Sales & Book Value Annual Sales$2.99 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.06 Book Value($13.60) per share Price / BookN/AMiscellaneous Outstanding Shares235,143,000Free Float232,321,000Market Cap$141 thousand OptionableNo Data Beta1.15 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ENDP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endo International plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Endo International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
